Lupin - Integrated Report 2025

We catalyze treatments that transform hope into healing

Inputs

Output

Outcomes

Financial
Capital

INPUTS

Our Financial Capital is invested strategically across different therapeutic areas for maximum capital efficiency.

Total Expenses: INR 209.5 Bn
CAPEX Allocation: INR 25.2 Bn

OUTPUT

Revenue from Operations: INR 280 Bn
EBITDA: INR 92 Bn
Dividend Paid: INR 5.5 Bn

OUTCOMES

A strengthened and resilient balance sheet enabling long-term value creation
Improved and consistent economic performance, driven by disciplined capital allocation
Enhanced company growth through strategic deployment of funds

Human
Capital

INPUTS

Our people are our most important assets, and their commitment to patients brings out the best in them.

Global Lupin Family: 26,000+
Expenditure on Benefits: INR 46 Bn
Total Training Hours: 1,528,456

OUTPUT

Employee Satisfaction Score: 85%
Certified as Great Place to Work: 13 Geographies
Human Rights Excellence: 17 Locations Platinum Certified
Employee Turnover Rate: 16.8%
Employee Volunteering Hours: 35,462

OUTCOMES

A high-performing, future-ready workforce aligned with organizational purpose
Employee well-being and engagement enhanced across roles, functions and geographies
Lower attrition, leading to higher productivity and commitment
An inclusive and diverse work environment
Strengthened leadership pipeline enabling long-term growth

Manufacturing
Capital

INPUTS

Our 15 state-of-the-art manufacturing facilities pave the way for sustainable operations to address patient needs.

OUTPUT

Manufacturing Output (Formulations): 22,538 Mn Units
Total Product Portfolio: 1,200+ Products
All Sites cGMP Compliant

OUTCOMES

Optimized manufacturing efficiencies through technology, automation, and process excellence
Enhanced production capacity to meet patient and market needs reliably
Enabled sustainable resource utilization across facilities
Improved operational resilience through modernization, digital, and AI interventions

Natural
Capital

INPUTS

Our balanced use of natural resources maximizes efficiencies while reducing impact on the environment.

Energy Consumption: 2.9 Mn GJ
Water Withdrawal: 1.7 Mn KL
Renewable Energy: 48% of Total Energy

OUTPUT

Emission Reduction: 41%
Water Recycling: 45%
Hazardous Waste Co-processing: 91%
Biodiversity Assessment: 66% Sites

OUTCOMES

Reduced environmental footprint through energy efficiency and renewable energy adoption
Improved water stewardship through recycling, reuse, and conservation initiatives
Strengthened waste management performance with increased diversion from landfills
Progressed toward long-term decarbonization targets

Intellectual
Capital

INPUTS

Our R&D centers enable us with a competitive advantage, while making therapies more accessible.

R&D Investment: INR 20,631 Mn
R&D Team: 1,400+
Global R&D Centers: 7

OUTPUT

Patent Applications in FY26: 66
Patents Granted in FY26: 125
Filings in FY26: 38
Approvals in FY26: 31
Kavach IT Training: 100% Employees Covered

OUTCOMES

Accelerated innovation through focused R&D programs and investments enabling future growth
Strengthened global IP portfolio supporting competitive advantage
Developed differentiated and accessible therapies for key therapeutic areas
Enhanced data integrity through robust, AI-driven digital and IT infrastructure

Social & Relationship
Capital

INPUTS

Our communities are extremely important stakeholders, and their enrichment is a priority for us.

CSR Spend: INR 363 Mn
Patient Outreach Programs: 10+

OUTPUT

Total CSR Beneficiaries: 510,805
Total Patients Reached: 2.6+ Mn
Local Sourcing (within India): 74%

OUTCOMES

Deepened supplier engagement and transparency across the value chain
Strengthened partnerships for sustainable development and mutual value creation
Improved healthcare access for underserved populations
Advanced community trust through impactful CSR and patient outreach initiatives
Enhanced stakeholder confidence driven by ethical and responsible business practices